Pathstone Holdings
PHAT icon

Pathstone Holdings’s Phathom Pharmaceuticals PHAT Stock Holding History

Pathstone Holdings’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$163K Hold
15,000
– – ﹤0.01% 2261
2026
Q1 		$167K Buy
15,000
+100
+0.7% +$1.26K ﹤0.01% 2129
2025
Q4 		$247K Buy
14,900
+4,578
+44% +$65.4K ﹤0.01% 2037
2025
Q3 		$121K Buy
+10,322
New +$107K ﹤0.01% 2256

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Pathstone Holdings's PHAT Position: Q2 2026 in Review

Pathstone Holdings held its Phathom Pharmaceuticals (PHAT) position steady in Q2 2026 at 15,000 shares worth $163K. The position accounts for ﹤0.01% of the portfolio, ranked #2261.

Pathstone Holdings first reported a position in PHAT in Q3 2025 and has held it in 4 quarters since. The position peaked at $247K in Q4 2025. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Pathstone Holdings held 15,000 shares of Phathom Pharmaceuticals worth $163K as of Q2 2026.
  • Pathstone Holdings left its Phathom Pharmaceuticals share count unchanged in Q2 2026.
  • Phathom Pharmaceuticals made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #2261 holding.
  • Pathstone Holdings first reported a position in Phathom Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Pathstone Holdings's Phathom Pharmaceuticals position peaked at $247K in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.